THE KPM GROUP DC LLC

THE KPM GROUP DC LLC filed a Q2 report for INOZYME PHARMA on July 17, 2025, reporting $20,000 in lobbying income.

Lobbying for INOZYME PHARMA · Treatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.

All filings by THE KPM GROUP DC LLC · Everything INOZYME PHARMA has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 17, 2025

Income

$20,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

H.R.1262/S.932 - Give Kids a Chance Act H.R.946 - ORPHAN Cures Act H.R. 1414 - Cameron's Law H.R.1532/S.822 - Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1492 - Ensuring Pathways to Innovative Cures (EPIC) Act

Bills named in this filing 7

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025
H.R. 946
ORPHAN Cures Act
H.R. 1414
Cameron’s Law
H.R. 1532
Scientific EXPERT Act of 2025
S. 822
Scientific EXPERT Act of 2025
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.